Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 2/20 | 0.40 |
| ▸ | DRD2 | P14416 | 2/20 | 0.40 |
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.39 |
| ▸ | MMP12 | P39900 | 1/20 | 0.36 |
| ▸ | CREBBP | Q92793 | 3/20 | 0.36 |
| ▸ | BRD4 | O60885 | 2/20 | 0.36 |
| ▸ | ADRB2 | P07550 | 10/20 | 0.35 |
| ▸ | ADRB1 | P08588 | 5/20 | 0.35 |
| ▸ | PARP1 | P09874 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4100740 | 0.84 | HTR1A (0.45) | HTR1ADRD2HTR2ASMYD3MMP12 | |
| SCHEMBL19697171 | 0.81 | HTR1A (0.41) | HTR1ADRD2HTR2ASMYD3MMP12 | |
| SCHEMBL19697172 | 0.79 | HTR1A (0.42) | HTR1ADRD2HTR2ASMYD3MMP12 | |
| SCHEMBL31364658 | 0.76 | SMYD3 (0.43) | HTR1ADRD2SMYD3MMP12CREBBP | |
| SCHEMBL17476273 | 0.73 | SMYD3 (0.44) | SMYD3ADRB2ADRB1 | |
| SCHEMBL17476275 | 0.73 | SMYD3 (0.44) | SMYD3ADRB2ADRB1 | |
| SCHEMBL17476311 | 0.73 | SMYD3 (0.44) | SMYD3ADRB2ADRB1 | |
| SCHEMBL22521052 | 0.72 | SMYD3 (0.45) | HTR1ADRD2HTR2ASMYD3MMP12 | |
| SCHEMBL1851941 | 0.72 | CREBBP (0.58) | HTR1ADRD2SMYD3MMP12CREBBP | |
| Hydrochloric Acid SCHEMBL17476307 | 0.72 | ADRB2 (0.46) | SMYD3ADRB2ADRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120022056-A1 | FUSED TRICYCLIC DERIVATIVES FOR THE TREATMENT OF PSYCHOTIC DISORDERS | BENTLEY JONATHAN (IT) | 2012-01-26 | — | — | US | disclosed |
| US-20120022056-A1 | FUSED TRICYCLIC DERIVATIVES FOR THE TREATMENT OF PSYCHOTIC DISORDERS | BENTLEY JONATHAN (IT) | 2012-01-26 | — | — | US | disclosed |
| US-20120022056-A1 | FUSED TRICYCLIC DERIVATIVES FOR THE TREATMENT OF PSYCHOTIC DISORDERS | BENTLEY JONATHAN (IT) | 2012-01-26 | — | — | US | disclosed |
| EP-1786822-A1 | FUSED TRICYCLIC DERIVATIVES FOR THE TREATMENT OF PSYCHOTIC DISORDERS | GLAXO GROUP LIMITED (GB) | 2007-05-23 | — | — | EP | disclosed |
| WO-2006024517-A1 | FUSED TRICYCLIC DERIVATIVES FOR THE TREATMENT OF PSYCHOTIC DISORDERS | GLAXO GROUP LIMITED (GB) | 2006-03-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120022056-A1 | FUSED TRICYCLIC DERIVATIVES FOR THE TREATMENT OF PSYCHOTIC DISORDERS | GABBR1, GABRQ, GABRE | HTR1A 7/4885DRD2 5/4885HTR2A 54/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.